Regnum Corp. (RGMP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -780.88 Thousand USD | -189.4% |
| 2021 | -269.83 Thousand USD | -129.3% |
| 2020 | -117.67 Thousand USD | -223.46% |
| 2019 | -36.38 Thousand USD | -1920.82% |
| 2018 | 1998.00 USD | 44.05% |
| 2017 | 1387.00 USD | 268.12% |
| 2016 | -825.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -201.51 Thousand USD | -47.27% |
| 2023 Q2 | - USD | 100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 FY | -780.88 Thousand USD | -189.4% |
| 2022 Q2 | -205.41 Thousand USD | 26.0% |
| 2022 Q1 | -277.6 Thousand USD | -4.81% |
| 2022 Q3 | -183.6 Thousand USD | 10.62% |
| 2022 Q4 | -136.83 Thousand USD | 25.47% |
| 2021 Q1 | -3340.00 USD | -365.83% |
| 2021 FY | -269.83 Thousand USD | -129.3% |
| 2021 Q2 | 96.51 Thousand USD | 2989.67% |
| 2021 Q4 | -264.85 Thousand USD | -169.86% |
| 2021 Q3 | -98.14 Thousand USD | -201.69% |
| 2020 FY | -117.67 Thousand USD | -223.46% |
| 2020 Q1 | -67.04 Thousand USD | -1133.33% |
| 2020 Q2 | -40.19 Thousand USD | 40.05% |
| 2020 Q4 | -717.00 USD | 92.62% |
| 2020 Q3 | -9722.00 USD | 75.81% |
| 2019 Q4 | -5436.00 USD | -6277.27% |
| 2019 FY | -36.38 Thousand USD | -1920.82% |
| 2019 Q2 | -7422.00 USD | 68.56% |
| 2019 Q1 | -23.61 Thousand USD | -12196.88% |
| 2019 Q3 | 88.00 USD | 101.19% |
| 2018 Q2 | 785.00 USD | -37.6% |
| 2018 Q3 | 147.00 USD | -81.27% |
| 2018 FY | 1998.00 USD | 44.05% |
| 2018 Q4 | -192.00 USD | -230.61% |
| 2018 Q1 | 1258.00 USD | 1023.21% |
| 2017 Q3 | 307.00 USD | -83.57% |
| 2017 Q1 | -900.00 USD | -227.27% |
| 2017 Q4 | 112.00 USD | -63.52% |
| 2017 Q2 | 1868.00 USD | 307.56% |
| 2017 FY | 1387.00 USD | 268.12% |
| 2016 Q4 | -275.00 USD | 0.0% |
| 2016 FY | -825.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 41.525% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 88.817% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 101.474% |
| Nascent Biotech, Inc. | -2.08 Million USD | 62.596% |
| Rebus Holdings, Inc. | -1.02 Million USD | 23.442% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 101.199% |
| Qrons Inc. | -789.34 Thousand USD | 1.072% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -23.479% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 98.753% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -87.949% |
| Skye Bioscience, Inc. | -37.64 Million USD | 97.926% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 98.958% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 88.125% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -185.619% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.017% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 73.002% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 57.107% |
| Mesoblast Limited | -87.95 Million USD | 99.112% |
| Marizyme, Inc. | -65.34 Million USD | 98.805% |
| Genus plc | 7.9 Million USD | 109.885% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 92.83% |
| Pharming Group N.V. | -10.54 Million USD | 92.597% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 64.011% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 78.953% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 91.17% |
| ContraFect Corporation | -65.15 Million USD | 98.801% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 84.018% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 54.796% |
| IMV Inc. | -36.48 Million USD | 97.86% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 90.311% |
| MultiCell Technologies, Inc. | -380.07 USD | -205358.731% |
| ONE Bio Corp. | 8.67 Million USD | 109.0% |
| Accustem Sciences Inc. | -3.74 Million USD | 79.156% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 98.489% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 38.374% |
| Q BioMed Inc. | -2.05 Million USD | 61.947% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 79.082% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 67.202% |
| Biomind Labs Inc. | -1.21 Million USD | 35.693% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 98.693% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 74.824% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 90.119% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 59.939% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -5114.256% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 95.08% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 86.576% |
| GB Sciences, Inc. | -1.36 Million USD | 42.653% |
| Alpha Cognition Inc. | -13.77 Million USD | 94.33% |
| HST Global, Inc. | -146.21 Thousand USD | -434.086% |
| CSL Limited | 2.64 Billion USD | 100.03% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 55.499% |
| Halberd Corporation | -79.67 Thousand USD | -880.078% |
| Enzolytics Inc. | -2.17 Million USD | 64.127% |
| Agentix Corp. | -1.37 Million USD | 43.176% |
| Resverlogix Corp. | -3.61 Million USD | 78.369% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 75.377% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.735% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 896.823% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 111.277% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 80.345% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 74.195% |
| AVAX Technologies, Inc. | -6.41 Million USD | 87.825% |
| Zenith Capital Corp. | -10.59 Million USD | 92.63% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.182% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -3259.81% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 81.165% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -1191.991% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 61.055% |
| Kadimastem Ltd | -3.3 Million USD | 76.39% |
| Helix BioMedix, Inc. | -1.05 Million USD | 26.056% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 79.553% |
| BioStem Technologies, Inc. | -8.48 Million USD | 90.795% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -76.924% |
| LadRx Corporation | 400.44 Thousand USD | 295.006% |
| Cell Source, Inc. | -5.32 Million USD | 85.325% |
| Regen BioPharma, Inc. | 1.02 Million USD | 176.295% |
| Regen BioPharma, Inc. | 1.02 Million USD | 176.295% |
| NovAccess Global Inc. | -4.76 Million USD | 83.626% |
| Affymax, Inc. | -14.42 Million USD | 94.586% |
| Itoco Inc. | -1.86 Million USD | 58.219% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 82.422% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 53.212% |
| Mobile Lads Corp. | -2.26 Million USD | 65.498% |
| CytoDyn Inc. | -49.84 Million USD | 98.433% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -888.052% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -242.304% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 17.062% |
| SYBLEU INC | -180.3 Thousand USD | -333.095% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 51.58% |
| International Stem Cell Corporation | -131 Thousand USD | -496.097% |
| Bioxytran, Inc. | -4.28 Million USD | 81.755% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -1338.84% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 69.138% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 98.376% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 63.061% |
| RenovaCare, Inc. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 75.351% |
| Neutra Corp. | -233.46 Thousand USD | -234.477% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 96.152% |
| PureTech Health plc | -65.69 Million USD | 98.811% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 96.328% |
| IXICO plc | -1.17 Million USD | 33.711% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 92.134% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 98.633% |
| CSL Limited | 2.64 Billion USD | 100.03% |
| Cellectis S.A. | -103.17 Million USD | 99.243% |